



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/660,897
		Filing Date	September 11, 2003
		First Named Inventor	Cheng H. JIN
		Art Unit	1634
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	8 + 23 REFERENCES	Attorney Docket Number	532232000800

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 (2 pages, plus duplicate) References (23) Return Receipt Postcard
Remarks CUSTOMER NO. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual name	MORRISON & FOERSTER LLP Bruce D. Grant - 47,608
Signature	
Date	January 22, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 22, 2004

Signature:


(Diane Blevins)



PATENT
Docket No. 532232000800

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 22, 2004.


Diane Blevins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Cheng He JIN et al.

Serial No.: 10/660,897

Filing Date: September 11, 2003

For: HIGH-THROUGHPUT METHODS FOR
IDENTIFYING QUADRUPLEX
FORMING NUCLEIC ACIDS AND
MODULATORS THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1634

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 532232000800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 21, 2004


Respectfully submitted,

By:



Bruce Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	Docket Number 532232000800	Application Number 10/660,897
	Applicant Cheng He JIN et al.	
	Filing Date September 11, 2003	Group Art Unit 1634
	Mailing Date January 22, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	1. ✓	Anantha et al., Biochemistry (1998) 37(9):2709-2714
	2. ✓	Arthanari et al., Nucleic Acids Research (1998) 26(16):3724-3728
	3. ✓	Arthanari et al., Anti-Cancer Drug Design (1999) 14:317-326
	4. ✓	Duan et al., Mol. Cancer Therapeutics (2001) 1:103
	5. ✓	Han et al., J. Am. Chem. Soc. (1999) 121:3561-3570
	6. ✓	Hurley, Nature Rev. Cancer (2000) 2:188-200
	7. ✓	Jing et al., J. Biomol. Struct. Dyn. (1997) 15:573-585
	8. ✓	Jing et al., J. Biol. Chem. (1998) 273:34992-34999
	9. ✓	Kelly et al., J. Mol. Biol. (1996) 256:417-422
	10. ✓	Lew et al., Proc. Natl. Acad. Sci. U.S.A. (2000) 97:12508-12512
	11. ✓	Li et al., Biochemistry (1996) 35:6911-6922
	12. ✓	Lipscomb et al., Biochemistry (1996) 35:2818-2823
	13. ✓	Marathias and Bolton, Biochemistry (1999) 38:4355-4364
	14. ✓	Matsugami et al., J. Mol. Biol. (2001) 313:255-269
	15. ✓	Postel et al., J. Bioenerg. Biomembr. (2000) 32:277-284

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 532232000800	Application Number 10/660,897
INFORMATION DISCLOSURE CITATION IN AN APPLICATION 		Applicant Cheng He JIN et al.	
		Filing Date September 11, 2003	Group Art Unit 1634
		Mailing Date January 22, 2004	
	1	Qu and Chaires, Methods Enzymol. (2000) 321:353-69	
	17.	Ren et al., Biochemistry (1999) 38:16067-16075	
	18.	Schultze et al., J. Mol. Biol. (1994) 235:1532-1547	
	19.	Shin-ya et al., J. Am. Chem. Soc. (2001) 123:1262	
	20.	Simonsson et al., Nucleic Acids Res. (1998) 26:1167-1172	
	21.	Simonsson and Sjoback, J. Biol. Chem. (1999) 274:17379-17383	
	22.	Sun et al., J. Med. Chem. (1997) 40:2113-2116	
	23.	Thomas et al., J. Phys. Chem. B. (2001) 105:12628-12633	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			